Pfizer and BioNTech said Wednesday that a final data analysis found their coronavirus vaccine was 95% effective in preventing Covid-19 and appeared to fend off severe disease. "The final analysis underlines the results of the positive interim efficacy analysis announced on November 9," BioNTech CEO Ugur Sahin said in a statement. The final analysis evaluated 170 confirmed Covid infections among the late-stage trial's more than 43,000 participants. The companies said 162 cases of Covid were observed in the placebo group versus eight cases observed in the group that received its two-dose vaccine. A safe and effective vaccine is seen by investors and policymakers as a solution to get the global economy back on track after the pandemic wreaked havoc on nearly every country.
